SCHEMBL14908472

SCHEMBL14908472

CN(C)OCC(C)(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13966614 0.75 CYP2C19 (0.32)
SCHEMBL22910425 0.73 CYP2C19 (0.31)
SCHEMBL28121611 0.73 NUDT1 (0.32)
SCHEMBL21320802 0.71 CYP2D6 (0.45)
SCHEMBL6753822 0.71
SCHEMBL6753826 0.71
SCHEMBL18125076 0.71
SCHEMBL23224295 0.69
SCHEMBL18471050 0.68 PIK3CD (0.32)
SCHEMBL18125068 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107540565-A The preparation of N, N (two) alkyl amino alkyl (methyl) acrylamide or corresponding ester and its quaternary ammonium salt 赢创罗姆有限公司 2018-01-05 CN disclosed
EP-2770977-B1 NOVEL DOSAGE FORM NEUROVIVE PHARMACEUTICAL AB (SE) 2017-07-12 EP disclosed
US-9504728-B2 Dosage form NEUROVIVE PHARMACEUTICAL AB (SE) 2016-11-29 US disclosed
US-9119853-B2 Sanglifehrin based compounds NEUROVIVE PHARMACEUTICAL AB (SE) 2015-09-01 US disclosed
US-20140234414-A1 Novel Dosage Form Abliva Ab (SE) 2014-08-21 US disclosed
WO-2013061052-A1 NOVEL DOSAGE FORM BIOTICA TECHNOLOGY LIMITED (GB) 2013-05-02 WO disclosed